Join to View Full Profile
800 Biesterfield Rd.Suite 210Elk Grove Village, IL 60007
Phone+1 847-437-3312
Fax+1 847-956-5107
Dr. Bank is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Bruce Bank is an oncologist in Elk Grove Village, IL and is affiliated with multiple hospitals in the area, including Advocate Good Shepherd Hospital, AMITA Health Elk Grove Village, Northwest Community Healthcare, and AMITA Health Hoffman Estates. He received his medical degree from New York University Grossman School of Medicine and has been in practice 37 years. He specializes in hematologic oncology and is experienced in breast cancer, hodgkin's lymphoma, hemolytic-uremic syndrome, bronchial cancer, and b-cell chronic lymphooid leukemia. He has 7 publications and over 250 citings.
Education & Training
Jacobi Medical Center/Albert Einstein College of MedicineResidency, Internal Medicine, 1980 - 1983
New York University School of MedicineClass of 1980
Certifications & Licensure
IL State Medical License 1991 - 2026
NJ State Medical License 1988 - 1993
NY State Medical License 1981 - 1992
American Board of Internal Medicine Internal Medicine- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OncoEMR, Flatiron Health, Inc., 2011, 2013-2017
- CMS Meaningful Use Stage 1 Certification OncoEMR, Altos Solutions, Inc, 2011, 2013-2017
- CMS Meaningful Use Stage 1 Certification OncoEMR, Flatiron Health, Inc., 2011, 2013-2017
Clinical Trials
- Cetuximab and/or Bevacizumab Combined With Combination Chemotherapy in Treating Patients With Metastatic Colorectal Cancer Start of enrollment: 2005 Nov 01
- Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 15
- CMR Rate of Newly Diagnosed CML-CP Patients Treated With Nilotinib Start of enrollment: 2010 Nov 01
Publications & Presentations
PubMed
- 4 citationsMulticenter validation of an RNA-based assay to predict anti-PD-1 disease control in patients with recurrent or metastatic head and neck squamous cell carcinoma: the P...Kevin C Flanagan, Jon Earls, Jeffrey Hiken, Rachel L Wellinghoff, Michelle M Ponder
Journal for Immunotherapy of Cancer. 2024-11-03 - 6 citationsMultidimensional biomarker predicts disease control in response to immunotherapy in recurrent or metastatic head and neck squamous-cell carcinoma.Kevin C Flanagan, Jon Earls, Ian Schillebeeckx, Jeffrey Hiken, Rachel L Wellinghoff
Journal of Cancer Research and Clinical Oncology. 2023-11-01 - 20 citationsConcurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung CancerRandy F. Sweis, Sachdev Thomas, Bruce Bank, Paul A. S. Fishkin, Colin Mooney
Cureus. 2016-02-26
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
